London, 24 June 2015: Technavio, the independent tech-focused global research firm, has published a report on the global kidney cancer drugs market 2015-2019, which is expected to grow at a CAGR of 7.36% during the forecast period of 2014-2019.
Availability of drugs that combat kidney cancer is one factor that drives market growth. Recent advances made in the field of technology and science has led to the development of kidney cancer drugs. Angiogenesis inhibitors, cytokine therapies, and immunomodulation therapeutics are examples of the different classes of kidney cancer drugs available in the market. Also, the provision of orphan drug designation and fast track designation for medications too propels market growth.
“Individuals tend to develop resistance to monotherapies over a period, resulting in the increased preference for combination therapies, which are safe and more effective in the treatment of kidney cancer,” says Faisal Ghaus, Vice President of Technavio.
“Combination drugs are selected depending upon the health condition of the patient and the severity of the disease.”
Key Market Drivers:
- Growing Patient Population.
- Special Regulatory Designation for Pipeline Molecules.
- Patient Assistance Programs.
- Increased R&D.
Key Market Trends:
- Strategic Alliances.
- Combination Therapies.
- Use of Off-label Drugs.
Key Market Vendors:
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Inc.
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
